474 related articles for article (PubMed ID: 31482064)
1. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.
Cao Y; Lu W; Sun R; Jin X; Cheng L; He X; Wang L; Yuan T; Lyu C; Zhao M
Front Oncol; 2019; 9():767. PubMed ID: 31482064
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
3. Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma.
Zhang Y; Geng H; Zeng L; Li J; Yang Q; Jia S; Zong X; Cai W; Liu S; Lu Y; Yu L; Li C; Wu D
Hematol Oncol; 2024 Jan; 42(1):e3227. PubMed ID: 37776326
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
5. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.
Huang C; Wu L; Liu R; Li W; Li Z; Li J; Liu L; Shan B
Ann Transl Med; 2020 Sep; 8(17):1048. PubMed ID: 33145267
[TBL] [Abstract][Full Text] [Related]
7. A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
Zhang Y; Li J; Lou X; Chen X; Yu Z; Kang L; Chen J; Zhou J; Zong X; Yang Z; Li M; Xu N; Jia S; Geng H; Chen G; Dai H; Tang X; Yu L; Wu D; Li C
Front Oncol; 2021; 11():664421. PubMed ID: 34113569
[TBL] [Abstract][Full Text] [Related]
8. A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma.
Liu X; Zhang Y; Li K; Liu Y; Xu J; Ma J; An L; Wang H; Chu X
Transl Oncol; 2021 Jul; 14(7):101085. PubMed ID: 33813229
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
Fu S; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292
[TBL] [Abstract][Full Text] [Related]
10. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.
Larson SM; Walthers CM; Ji B; Ghafouri SN; Naparstek J; Trent J; Chen JM; Roshandell M; Harris C; Khericha M; Schweppe T; Berent-Maoz B; Gosliner SB; Almaktari A; Ceja MA; Allen-Auerbach MS; Said J; Nawaly K; Mead M; de Vos S; Young PA; Oliai C; Schiller GJ; Timmerman JM; Ribas A; Chen YY
Cancer Discov; 2023 Mar; 13(3):580-597. PubMed ID: 36416874
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma.
Xin X; Zhu X; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Li C; Cao Y; Meng F; Jiang L; Zhang Y
Cell Oncol (Dordr); 2024 Apr; ():. PubMed ID: 38564164
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis.
Nguyen TT; Thanh Nhu N; Chen CL; Lin CF
Cancer Med; 2023 Sep; 12(18):18767-18785. PubMed ID: 37667978
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of CRISPR-based non-viral
Hu Y; Zu C; Zhang M; Wei G; Li W; Fu S; Hong R; Zhou L; Wu W; Cui J; Wang D; Du B; Liu M; Zhang J; Huang H
EClinicalMedicine; 2023 Jun; 60():102010. PubMed ID: 37251628
[TBL] [Abstract][Full Text] [Related]
14. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
Front Immunol; 2022; 13():969660. PubMed ID: 36059523
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
Mu J; Deng H; Lyu C; Yuan J; Li Q; Wang J; Jiang Y; Deng Q; Shen J
Hematol Oncol; 2023 Apr; 41(2):275-284. PubMed ID: 35195933
[TBL] [Abstract][Full Text] [Related]
16. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
17. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.
Onea AS; Jazirehi AR
Am J Cancer Res; 2016; 6(2):403-24. PubMed ID: 27186412
[TBL] [Abstract][Full Text] [Related]
18. A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma.
Ying Z; He T; Jin S; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Liu W; Deng L; Ding Y; Hu X; Bu B; Lu X; Song Y; Zhu J
Chin J Cancer Res; 2022 Feb; 34(1):53-62. PubMed ID: 35355931
[TBL] [Abstract][Full Text] [Related]
19. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Zhang Y; Patel RP; Kim KH; Cho H; Jo JC; Jeong SH; Oh SY; Choi YS; Kim SH; Lee JH; Angelos M; Guruprasad P; Cohen I; Ugwuanyi O; Lee YG; Pajarillo R; Cho JH; Carturan A; Paruzzo L; Ghilardi G; Wang M; Kim S; Kim SM; Lee HJ; Park JH; Cui L; Lee TB; Hwang IS; Lee YH; Lee YJ; Porazzi P; Liu D; Lee Y; Kim JH; Lee JS; Yoon DH; Chung J; Ruella M
Mol Cancer; 2023 Dec; 22(1):200. PubMed ID: 38066564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
